AstraZeneca accepts charity to trial olaparib in glioblastoma
This article was originally published in Scrip
Executive Summary
AstraZeneca's investigational cancer treatment olaparib, acquired when the pharma giant bought KuDOS Pharmaceuticals in 2005, is being tested alongside temozolomide in a new Phase I trial in patients with recurrent glioblastoma that requires surgery.